1 week ago
UPL Shares Slide 28% as Advanta IPO Offers Recovery Potential
UPL is a company that sells farming products and seeds.
Its stock price has fallen about 28% in 2026.
Jefferies believes the lower price could give investors a chance to benefit if the company improves.
UPL’s seed business, Advanta, is expected to grow strongly in FY27.
UPL is also spending more on new markets and distribution.
The company is closing or reducing activities that do not earn enough money.
In Latin America, it is keeping tighter control of its inventory because El Nino could reduce farm demand.
Advanta’s approved IPO could also help show the value of that business, although stronger-than-expected El Nino conditions remain a risk.
UPL’s share price has fallen about 28% so far in 2026.
Jefferies retained its Buy rating and set a Rs 715 target, implying about 26% upside.
Jefferies expects Advanta to deliver strong double-digit revenue and EBITDA growth in FY27.
UPL is exiting lower-return businesses and tightening inventory controls in Latin America.
SEBI has approved Advanta’s IPO, which management plans to market soon.
- Who
- UPL, its Advanta seeds business, and Jefferies.
- What
- UPL’s stock has fallen about 28% in 2026, while Jefferies expects potential recovery based on Advanta growth, improved margins, inventory controls, and the Advanta IPO.
- Where
- The business developments involve UPL’s operations in Latin America and the acquisition of Misr Hytech Seeds in Egypt.
- When
- The share decline occurred so far in 2026; Jefferies’ projections concern FY27, and the Advanta IPO marketing is planned soon.
- Why
- Jefferies believes UPL’s valuation has become more reasonable and that operational improvements and the Advanta IPO could support earnings and value.
Jefferies’ Recovery Case
Risks and Cautions
Earnings growth
Jefferies’ Recovery Case
Jefferies expects Advanta’s revenue and EBITDA to grow strongly in double digits in FY27, while UPL’s margin improvements could support 14% EBITDA growth.
Risks and Cautions
The expected improvement depends on stronger Advanta performance and UPL’s ability to exit lower-return products, geographies, and joint ventures.
Latin American demand
Jefferies’ Recovery Case
Tighter inventory controls in Latin America could help UPL manage stock more carefully.
Risks and Cautions
A stronger-than-expected El Nino in Brazil and Latin America could weaken agricultural demand and affect inventory levels.
Value creation
Jefferies’ Recovery Case
Jefferies believes the 28% share-price decline has lowered market expectations, while the Advanta IPO could unlock value.
Risks and Cautions
The IPO is a potential catalyst but has not yet been completed; investors must also consider that the article’s target price and rating come from a brokerage report.
Key facts
- Stock performance
- UPL shares have corrected about 28% so far in 2026.
- Jefferies rating
- Jefferies retained its Buy rating on UPL.
- Target price
- Jefferies set a target price of Rs 715, implying about 26% upside.
- Advanta outlook
- Management expects strong double-digit revenue and EBITDA growth in FY27.
- Acquisition
- UPL acquired Egypt-based Misr Hytech Seeds for US$110 million; management estimates an internal rate of return of about 30%.
- Margin forecast
- Jefferies expects a 50-basis-point EBITDA margin improvement and 14% year-on-year EBITDA growth in FY27.
- IPO status
- The Securities and Exchange Board of India has approved Advanta’s IPO.
Quotes
Jefferies
Brokerage firm covering UPL
“Advanta should deliver strong double-digit revenue/Ebitda growth.”
financialexpress.com
“Undemanding valuations, maintain Buy.”
financialexpress.com
Sources
Related news
Jefferies Recommends Four Stocks With Up To 37% Upside
Engineers India stock rises 21% in a month
Jefferies Sees 28% Upside in Allied Blenders Stock
Jefferies Retains Buy Calls on Three Stocks With Upside
Top Brokerages Bullish on 8 Stocks With Up to 42% Upside
India, Brazil Agree to Double Trade by 2030
India Leads Largest Business Delegation to Argentina to Expand Cooperation
Argentina Moves to Lower Barriers for Indian Pharma Trade
